According to previous studies, interleukin-6 (IL-6) can activate JAK2/STAT3 signaling, and repression of the IL-6/JAK2/STAT3 signaling axis has been reported to inhibit the migration, invasion, and tumor formation of breast cancer cells [41,42,43]. Here, JAK2 is linked to breast carcinoma.